BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Z, He D, Zeng YY, Zhu L, Yang C, Lu YJ, Huang JQ, Cheng XY, Huang XH, Tan XJ. The spleen may be an important target of stem cell therapy for stroke. J Neuroinflammation 2019;16:20. [PMID: 30700305 DOI: 10.1186/s12974-019-1400-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Jafarzadeh-Esfehani R, Soudyab M, Parizadeh SM, Jaripoor ME, Nejad PS, Shariati M, Nabavi AS. Circulating Exosomes and Their Role in Stroke. Curr Drug Targets 2020;21:89-95. [PMID: 31433753 DOI: 10.2174/1389450120666190821153557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Brown J, Kingsbury C, Lee JY, Vandenbark AA, Meza-Romero R, Offner H, Borlongan CV. Spleen participation in partial MHC class II construct neuroprotection in stroke. CNS Neurosci Ther 2020;26:663-9. [PMID: 32237074 DOI: 10.1111/cns.13369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Gaidhani N, Kem WR, Uteshev VV. Spleen is not required for therapeutic effects of 4OH-GTS-21, a selective α7 nAChR agonist, in the sub-acute phase of ischemic stroke in rats. Brain Res 2021;1751:147196. [PMID: 33159972 DOI: 10.1016/j.brainres.2020.147196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Smith JN, Dawson DM, Christo KF, Jogasuria AP, Cameron MJ, Antczak MI, Ready JM, Gerson SL, Markowitz SD, Desai AB. 15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration. JCI Insight 2021;6:143658. [PMID: 33600377 DOI: 10.1172/jci.insight.143658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Juli C, Heryaman H, Nazir A, Ang ET, Defi IR, Gamayani U, Atik N. The Lymphocyte Depletion in Patients with Acute Ischemic Stroke Associated with Poor Neurologic Outcome. Int J Gen Med 2021;14:1843-51. [PMID: 34017192 DOI: 10.2147/IJGM.S308325] [Reference Citation Analysis]
6 Suda S, Nito C, Yokobori S, Sakamoto Y, Nakajima M, Sowa K, Obinata H, Sasaki K, Savitz SI, Kimura K. Recent Advances in Cell-Based Therapies for Ischemic Stroke. Int J Mol Sci 2020;21:E6718. [PMID: 32937754 DOI: 10.3390/ijms21186718] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Kawabori M, Shichinohe H, Kuroda S, Houkin K. Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke. Int J Mol Sci 2020;21:E7380. [PMID: 33036265 DOI: 10.3390/ijms21197380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Malone K, Diaz Diaz AC, Shearer JA, Moore AC, Waeber C. The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia. J Neuroinflammation 2021;18:37. [PMID: 33516262 DOI: 10.1186/s12974-021-02083-5] [Reference Citation Analysis]
9 Choi YH, Laaker C, Hsu M, Cismaru P, Sandor M, Fabry Z. Molecular Mechanisms of Neuroimmune Crosstalk in the Pathogenesis of Stroke. Int J Mol Sci 2021;22:9486. [PMID: 34502395 DOI: 10.3390/ijms22179486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu W, Bai X, Zhang A, Huang J, Xu S, Zhang J. Role of Exosomes in Central Nervous System Diseases. Front Mol Neurosci 2019;12:240. [PMID: 31636538 DOI: 10.3389/fnmol.2019.00240] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis]
11 Huang AP, Hsu YH, Wu MS, Tsai HH, Su CY, Ling TY, Hsu SH, Lai DM. Potential of stem cell therapy in intracerebral hemorrhage. Mol Biol Rep 2020;47:4671-80. [PMID: 32415506 DOI: 10.1007/s11033-020-05457-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]